Study of vepugratinib for cancers with FGFR3 gene changes
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests a new pill, vepugratinib, for people whose cancer has a specific change in a gene called FGFR3. The drug targets this gene change to try to slow or shrink the cancer, and may be an option if standard treatments have not worked.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your cancer must have a specific change (mutation) in the FGFR3 gene.
- You must have advanced cancer that has spread or cannot be removed by surgery, or in some cases, early-stage bladder cancer.
- For most parts of the study, you need to have tumors that can be measured on scans.
- You need to be in reasonably good health (able to do light activities) to take part.
- You cannot have untreated or uncontrolled brain tumors or certain eye problems.
- You must not be pregnant or breastfeeding during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug called Vepugratinib for people with advanced urinary tract cancer that has a specific change in the FGFR3 gene. It may be an option if you haven't had other treatments for advanced cancer and are looking for a new approach.
This study tests an oral medication (vepugratinib) that targets a specific gene change (FGFR3) found in some bladder cancers. It is for people with low-grade, non-invasive bladder cancer that has not spread into the muscle, to see if the drug can help control the cancer.
This expanded access program provides the investigational drug vepugratinib to people with advanced cancers (especially bladder cancer) that have a specific genetic change (FGFR3 mutation) and who have run out of standard treatment options. The goal is to give access to a potential new therapy outside of a clinical trial.
This trial tests a new drug, 3HP-327, for people with advanced solid tumors that have certain changes in the FGFR2 gene and have not responded to standard treatments. The goal is to see if the drug can shrink tumors or slow their growth.
This trial tests a combination of two drugs—pemigatinib, which targets tumors with certain FGFR gene changes, and an immunotherapy drug that helps the immune system fight cancer—for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if this combination can shrink tumors or slow their growth.
This trial tests a targeted drug called pemigatinib for advanced solid tumors that have a specific change in the FGFR gene. The goal is to see if the drug can slow tumor growth for people who have few other treatment options.
Hear when a new Urinary Bladder Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.